Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 9/20 | 0.40 |
| ▸ | ANPEP | P15144 | 5/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | CTSS | P25774 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | PEPD | P12955 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL697618 | 1.00 | MMP2 (0.40) | MMP2ANPEPTP53ALDH1A1CYP3A4 | |
| SCHEMBL697247 | 0.88 | MMP2 (0.39) | MMP2ANPEPTP53ALDH1A1CYP3A4 | |
| SCHEMBL2105252 | 0.88 | MMP2 (0.39) | MMP2ANPEPTP53ALDH1A1CYP3A4 | |
| SCHEMBL696018 | 0.84 | MMP2 (0.44) | MMP2ANPEPTP53ALDH1A1MEN1 | |
| SCHEMBL2105273 | 0.84 | MMP2 (0.44) | MMP2ANPEPTP53ALDH1A1MEN1 | |
| SCHEMBL699042 | 0.79 | NR1H2 (0.39) | MMP2ANPEPTP53ALDH1A1CYP3A4 | |
| SCHEMBL696717 | 0.79 | MMP2 (0.35) | MMP2ANPEPTP53ALDH1A1CYP3A4 | |
| SCHEMBL2105235 | 0.76 | MMP2 (0.47) | MMP2ANPEPCYP3A4CTSSMEN1 | |
| SCHEMBL694851 | 0.76 | MMP2 (0.47) | MMP2ANPEPCYP3A4CTSSMEN1 | |
| SCHEMBL2104430 | 0.73 | CTSS (0.54) | MMP2CTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2421826-B1 | PROLINE DERIVATIVES AS CATHEPSIN INHIBITORS | HOFFMANN LA ROCHE (CH) | 2013-10-23 | — | — | EP | disclosed |
| US-8163793-B2 | Proline derivatives | HOFFMAN-LA ROCHE INC. (US) | 2012-04-24 | — | — | US | disclosed |
| US-20100267722-A1 | NOVEL PROLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267722-A1 | NOVEL PROLINE DERIVATIVES | PRAP1, PRR12, SLC6A7 | MMP2 1229/4885ANPEP 107/4885TP53 3172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.